Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 310981, 11 pages
http://dx.doi.org/10.1155/2014/310981
Research Article

Enhanced Amelioration of High-Fat Diet-Induced Fatty Liver by Docosahexaenoic Acid and Lysine Supplementations

1Department of Animal Science and Technology, National Taiwan University, No. 50, Lane 155, Section 3, Keelung Road, Da'an District, Taipei City 106, Taiwan
2Institute of Biotechnology, National Taiwan University, No. 81, Changxing Street, Da'an District, Taipei City 106, Taiwan

Received 14 November 2013; Revised 15 April 2014; Accepted 29 April 2014; Published 25 May 2014

Academic Editor: Kanato Yamagata

Copyright © 2014 Hsin-Yu Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Hamaguchi, T. Kojima, N. Takeda et al., “The metabolic syndrome as a predictor of nonalcoholic fatty liver disease,” Annals of Internal Medicine, vol. 143, no. 10, pp. 722–I70, 2005. View at Google Scholar · View at Scopus
  2. J. K. Reddy and M. S. Rao, “Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 290, no. 5, pp. G852–G858, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Angulo, “Nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 346, no. 16, pp. 1221–1231, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. M. F. Gregor and G. S. Hotamisligil, “Inflammatory mechanisms in obesity,” Annual Review of Immunology, vol. 29, pp. 415–445, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Lotersztajn, B. Julien, F. Teixeira-Clerc, P. Grenard, and A. Mallat, “Hepatic fibrosis: molecular mechanisms and drug targets,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 605–628, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Marra, A. Gastaldelli, G. Svegliati Baroni, G. Tell, and C. Tiribelli, “Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis,” Trends in Molecular Medicine, vol. 14, no. 2, pp. 72–81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Thoma, C. P. Day, and M. I. Trenell, “Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review,” Journal of Hepatology, vol. 56, no. 1, pp. 255–266, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. L. A. Adams and P. Angulo, “Treatment of non-alcoholic fatty liver disease,” Postgraduate Medical Journal, vol. 82, no. 967, pp. 315–322, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Stillwell, “Docosahexaenoic acid: a most unusual fatty acid,” Chemistry and Physics of Lipids, vol. 153, no. 1, pp. 1–2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. C. M. Depner, K. A. Philbrick, and D. B. Jump, “Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr−/− mouse model of western diet-induced nonalcoholic steatohepatitis,” Journal of Nutrition, vol. 143, no. 3, pp. 315–323, 2013. View at Publisher · View at Google Scholar
  11. D. M. Fedor, Y. Adkins, B. E. Mackey, and D. S. Kelley, “Docosahexaenoic acid prevents trans-10, cis-12-conjugated linoleic acid-induced nonalcoholic fatty liver disease in mice by altering expression of hepatic genes regulating fatty acid synthesis and oxidation,” Metabolic Syndrome and Related Disorders, vol. 10, no. 3, pp. 175–180, 2012. View at Publisher · View at Google Scholar
  12. M. Capanni, F. Calella, M. R. Biagini et al., “Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 8, pp. 1143–1151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Arai, H. J. Kim, H. Chiba, and A. Matsumoto, “Anti-obesity effect of fish oil and fish oil-fenofibrate combination in female KK mice,” Journal of Atherosclerosis and Thrombosis, vol. 16, no. 5, pp. 674–683, 2009. View at Google Scholar · View at Scopus
  14. A. Gonzalez-Periz, A. Planaguma, K. Gronert et al., “Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA,” The FASEB Journal, vol. 20, no. 14, pp. 2537–2539, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. C. C. Tai, C. Y. Chen, H. S. Lee et al., “Docosahexaenoic acid enhances hepatic serum amyloid a expression via protein kinase a-dependent mechanism,” The Journal of Biological Chemistry, vol. 284, no. 47, pp. 32239–32247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Civitelli, D. T. Villareal, D. Agnusdei, P. Nardi, L. V. Avioli, and C. Gennari, “Dietary L-lysine and calcium metabolism in humans,” Nutrition, vol. 8, no. 6, pp. 400–405, 1992. View at Google Scholar · View at Scopus
  17. G. P. Vennart, V. P. Perna, and W. B. Stewart, “Fatty liver of portal type: cured by lysine plus tryptophan,” Journal of Nutrition, vol. 64, no. 4, pp. 635–638, 1958. View at Google Scholar
  18. R. Viviani, A. M. Sechi, and G. Lenaz, “Fatty acid composition of portal fatty liver in lysine-and threonine-deficient rats,” Journal of Lipid Research, vol. 15, pp. 52–56, 1964. View at Google Scholar · View at Scopus
  19. B. Wang, M. Ishihara, Y. Egashira, T. Ohta, and H. Sanada, “Effects of various kinds of dietary amino acids on the hepatotoxic action of D-galactosamine in rats,” Bioscience, Biotechnology and Biochemistry, vol. 63, no. 2, pp. 319–322, 1999. View at Google Scholar · View at Scopus
  20. Q. Deng, H. She, J. H. Cheng et al., “Steatohepatitis induced by intragastric overfeeding in mice,” Hepatology, vol. 42, no. 4, pp. 905–914, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. T. D. Schmittgen, B. A. Zakrajsek, A. G. Mills, V. Gorn, M. J. Singer, and M. W. Reed, “Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods,” Analytical Biochemistry, vol. 285, no. 2, pp. 194–204, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. M. D. Weltman, G. C. Farrell, and C. Liddle, “Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation,” Gastroenterologyno, vol. 111, no. 6, pp. 1645–1653, 1996. View at Publisher · View at Google Scholar
  23. P. Letteron, A. Sutton, A. Mansouri, B. Fromenty, and D. Pessayre, “Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice,” Hepatology, vol. 38, no. 1, pp. 133–140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. J. N. Baumgardner, K. Shankar, L. Hennings, T. M. Badger, and M. J. Ronis, “A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 294, no. 1, pp. G27–G38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. U. Ahmed, T. G. Redgrave, and P. S. Oates, “Effect of dietary fat to produce non-alcoholic fatty liver in the rat,” Journal of Gastroenterology and Hepatology, vol. 24, no. 8, pp. 1463–1471, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Hamazaki, M. Itomura, M. Huan et al., “n-3 long-chain FA decrease serum levels of TG and remnant-like particle-cholesterol in humans,” Lipids, vol. 38, no. 4, pp. 353–358, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Schenk, M. Saberi, and J. M. Olefsky, “Insulin sensitivity: modulation by nutrients and inflammation,” Journal of Clinical Investigation, vol. 118, no. 9, pp. 2992–3002, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Sun, Z. W. Wei, and Y. Li, “DHA regulates lipogenesis and lipolysis genes in mice adipose and liver,” Molecular Biology Reports, vol. 38, no. 2, pp. 731–737, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. P. A. Edwards, D. Tabor, H. R. Kast, and A. Venkateswaran, “Regulation of gene expression by SREBP and SCAP,” Biochimica et Biophysica Acta, vol. 1529, no. 1–3, pp. 103–113, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. D. S. Sachan, T. H. Rhew, and R. A. Ruark, “Ameliorating effects of carnitine and its precursors on alcohol-induced fatty liver,” The American Journal of Clinical Nutrition, vol. 39, no. 5, pp. 738–744, 1984. View at Google Scholar · View at Scopus